Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCQ | Q04759 | 20/20 | 0.50 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.45 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.45 |
| ▸ | CDK1 | P06493 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | PIM1 | P11309 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | PRKACA | P17612 | 1/20 | 0.45 |
| ▸ | CDK2 | P24941 | 1/20 | 0.45 |
| ▸ | MATK | P42679 | 1/20 | 0.45 |
| ▸ | FRK | P42685 | 1/20 | 0.45 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.45 |
| ▸ | CLK2 | P49760 | 1/20 | 0.45 |
| ▸ | GSK3A | P49840 | 1/20 | 0.45 |
| ▸ | GSK3B | P49841 | 1/20 | 0.45 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.45 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.45 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.45 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13671975 | 1.00 | PRKCQ (0.50) | PRKCQDCLK1MAP4K4CDK1CYP3A4 | |
| SCHEMBL4479025 | 0.92 | PRKCQ (0.51) | PRKCQ | |
| SCHEMBL13671974 | 0.92 | PRKCQ (0.51) | PRKCQ | |
| SCHEMBL13671886 | 0.90 | PRKCQ (0.49) | PRKCQDCLK1MAP4K4CDK1CYP3A4 | |
| SCHEMBL4464167 | 0.90 | PRKCQ (0.49) | PRKCQDCLK1MAP4K4CDK1CYP3A4 | |
| SCHEMBL13671972 | 0.88 | PRKCQ (0.45) | PRKCQDCLK1MAP4K4CDK1CYP3A4 | |
| SCHEMBL4477593 | 0.88 | PRKCQ (0.45) | PRKCQDCLK1MAP4K4CDK1CYP3A4 | |
| SCHEMBL4484939 | 0.87 | PRKCQ (0.44) | PRKCQDCLK1MAP4K4CDK1CYP3A4 | |
| SCHEMBL13671969 | 0.87 | PRKCQ (0.44) | PRKCQDCLK1MAP4K4CDK1CYP3A4 | |
| SCHEMBL13671941 | 0.85 | PRKCQ (0.60) | PRKCQDCLK1MAP4K4CDK1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7601714-B2 | Pyrimidine derivatives useful as inhibitors of PKC-theta | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-10-13 | — | — | US | disclosed |
| US-20080287410-A1 | PYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF PKC-THETA | BARBOSA ANTONIO J M | 2008-11-20 | — | — | US | disclosed |
| EP-1765791-A1 | PYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF PKC-THETA | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2007-03-28 | — | — | EP | disclosed |
| WO-2006014482-A1 | PYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF PKC-THETA | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-02-09 | — | — | WO | disclosed |
| US-20060025433-A1 | Pyrimidine derivatives useful as inhibitors of PKC-theta | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287410-A1 | PYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF PKC-THETA | PRKCZ, PRKCQ, PRKCH | PRKCQ 2/4885DCLK1 647/4885MAP4K4 407/4885 |
| US-20060025433-A1 | Pyrimidine derivatives useful as inhibitors of PKC-theta | PRKCZ, PRKCQ, PRKCH | PRKCQ 2/4885DCLK1 647/4885MAP4K4 407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.